Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2023-04-07 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙独立董事关于第十一届董事会第五次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinions on matters to be submitted to the company's board meeting, including the 2022 profit distribution plan and the appointment of the 2023 audit firm. It references internal governance rules and regulatory guidelines but does not contain financial statements or detailed financial data. The document is short (753 characters) and serves as a formal opinion or announcement related to board meeting agenda items rather than the meeting materials themselves or a full report. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including approvals and opinions on corporate governance issues.
2023-04-07 Chinese
马应龙独立董事关于第十一届董事会第五次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinions on matters to be discussed at the company's 11th board meeting, including the 2022 profit distribution plan and the appointment of the 2023 audit firm. It references internal governance rules and regulatory guidelines but does not contain financial statements or detailed financial data. The document is related to board/management information about governance and approvals rather than a full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-04-07 Chinese
马应龙关于出售股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a share equity sale by the company. It details the board meeting approval, the transaction price, the receipt of payment, and the expected non-recurring gain. It does not contain full financial statements or comprehensive financial performance data. The document is a specific transaction update related to capital structure changes (sale of shares). Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on a transaction, not a full report or regulatory filing.
2023-03-23 Chinese
马应龙独立董事关于出售股权退出与关联方共同投资企业暨关联交易的事前认可意见
Regulatory Filings
2022-12-13 Chinese
马应龙关于出售股权退出与关联方共同投资企业暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the sale of equity and related party transactions by the company 马应龙药业集团股份有限公司. It details the transaction parties, pricing, payment arrangements, and approvals by the board of directors. The document includes information about the transaction's impact and risk warnings but does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory announcement about a specific capital transaction involving related parties, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive transaction details, confirming it is not merely a report publication announcement or a regulatory filing fallback.
2022-12-13 Chinese
马应龙独立董事关于出售股权退出与关联方共同投资企业暨关联交易的独立意见
Regulatory Filings
2022-12-13 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.